Download this free whitepaper to learn more.
NeoGenomics’ latest white paper explores how actionable and emerging biomarkers are transforming therapeutic strategies in gastric and gastroesophageal junction cancers. With a focus on real-world data and clinical trial insights, the paper highlights how biomarker-driven decisions are enabling more personalized and effective care.
Key Highlights:
- CLDN18.2 is a leading biomarker driving new targeted therapies, including zolbetuximab and CAR-T innovations.
- NeoGenomics data supports biomarker-guided treatment, with high prevalence of PD-L1 and CLDN18.2.
- Clinical trials confirm improved outcomes with biomarker-driven approaches.
- Precision oncology is advancing with novel therapies like ADCs, bispecifics, and CAR-T.
This white paper is a must-read for oncology professionals seeking to stay ahead of the curve in precision medicine and biomarker-guided treatment.
Offered Free by: NeoGenomics
See All Resources from: NeoGenomics
